547 related articles for article (PubMed ID: 12548045)
1. Radioiodine lobar ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer.
Bal CS; Kumar A; Pant GS
Nucl Med Commun; 2003 Feb; 24(2):203-8. PubMed ID: 12548045
[TBL] [Abstract][Full Text] [Related]
2. A prospective clinical trial to assess the efficacy of radioiodine ablation as an alternative to completion thyroidectomy in patients with differentiated thyroid cancer undergoing sub-total thyroidectomy.
Bal CS; Kumar A; Chandra P; Dwivedi SN; Pant GS
Acta Oncol; 2006; 45(8):1067-72. PubMed ID: 17118841
[TBL] [Abstract][Full Text] [Related]
3. Treatment for microcarcinoma of the thyroid--clinical experience.
Küçük NO; Tari P; Tokmak E; Aras G
Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
[TBL] [Abstract][Full Text] [Related]
4. Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid.
Randolph GW; Daniels GH
Thyroid; 2002 Nov; 12(11):989-96. PubMed ID: 12490076
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients.
Bal CS; Kumar A; Pant GS
J Clin Endocrinol Metab; 2004 Apr; 89(4):1666-73. PubMed ID: 15070929
[TBL] [Abstract][Full Text] [Related]
6. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
Rosário PW; Calsolari MR
Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
[TBL] [Abstract][Full Text] [Related]
7. Differentiated thyroid cancer: radioiodine following lobectomy - a clinical feasibility study.
Hoyes KP; Owens SE; Millns MM; Allan E
Nucl Med Commun; 2004 Mar; 25(3):245-51. PubMed ID: 15094442
[TBL] [Abstract][Full Text] [Related]
8. Incidental multifocal papillary microcarcinomas of the thyroid: is subtotal thyroidectomy combined with radioiodine ablation enough?
Dietlein M; Luyken WA; Schicha H; Larena-Avellaneda A
Nucl Med Commun; 2005 Jan; 26(1):3-8. PubMed ID: 15604941
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine ablation of residual tissue in thyroid cancer: relationship between administered activity, neck uptake and outcome.
Logue JP; Tsang RW; Brierley JD; Simpson WJ
Br J Radiol; 1994 Nov; 67(803):1127-31. PubMed ID: 7820407
[TBL] [Abstract][Full Text] [Related]
10. Randomised comparison of 1.1 GBq and 3.7 GBq radioiodine to ablate the thyroid in the treatment of low-risk thyroid cancer: a 13-year follow-up.
Ahtiainen V; Vaalavirta L; Tenhunen M; Joensuu H; Mäenpää H
Acta Oncol; 2020 Sep; 59(9):1064-1071. PubMed ID: 32603613
[No Abstract] [Full Text] [Related]
11. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
12. Fractionated dosage of radioiodine for the ablation of low-risk differentiated thyroid cancer has no impact on survival.
Woliński K; Czepczyński R; Stangierski A; Trojanowski M; Rewaj-Łosyk M; Ziemnicka K; Bączyk M; Dyzmann-Sroka A; Ruchała M
Endokrynol Pol; 2018; 69(3):230-234. PubMed ID: 29504625
[TBL] [Abstract][Full Text] [Related]
13. Low versus high radioiodine dose in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid carcinoma: a large randomized clinical trial.
Fallahi B; Beiki D; Takavar A; Fard-Esfahani A; Gilani KA; Saghari M; Eftekhari M
Nucl Med Commun; 2012 Mar; 33(3):275-82. PubMed ID: 22124360
[TBL] [Abstract][Full Text] [Related]
14. Ablation of remaining functioning thyroid lobe with radioiodine after hemithyroidectomy for carcinoma.
Arad E; O'Mara RE; Wilson GA
Clin Nucl Med; 1993 Aug; 18(8):662-3. PubMed ID: 8403696
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
16. [Optimization of 131I ablation in patients with differentiated thyroid carcinoma: comparison of early outcomes of treatment with 100 mCi versus 60 mCi].
Kukulska A; Krajewska J; Roskosz J; Handkiewicz-Junak D; Jarzab M; Paliczka E; Puch Z; Wygoda Z; Gubała E; Jarzab B
Endokrynol Pol; 2006; 57(4):374-9. PubMed ID: 17006839
[TBL] [Abstract][Full Text] [Related]
17. Radiation dose assessment in radioiodine therapy. Dose-response relationships in differentiated thyroid carcinoma using quantitative scanning and PET.
O'Connell ME; Flower MA; Hinton PJ; Harmer CL; McCready VR
Radiother Oncol; 1993 Jul; 28(1):16-26. PubMed ID: 8234866
[TBL] [Abstract][Full Text] [Related]
18. Lithium as an adjuvant in the postoperative ablation of remnant tissue in low-risk thyroid carcinoma.
Yamazaki CA; Padovani RP; Biscolla RP; Ikejiri ES; Marchetti RR; Castiglioni ML; Matsumura LK; Maciel RM; Furlanetto RP
Thyroid; 2012 Oct; 22(10):1002-6. PubMed ID: 22953991
[TBL] [Abstract][Full Text] [Related]
19. A comparison of low versus high radioiodine administered activity in patients with low-risk differentiated thyroid cancer.
Ben Ghachem T; Yeddes I; Meddeb I; Bahloul A; Mhiri A; Slim I; Ben Slimene MF
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):655-660. PubMed ID: 27225282
[TBL] [Abstract][Full Text] [Related]
20. Influence of diagnostic and therapeutic doses on thyroid remnant ablation rates.
Karam M; Gianoukakis A; Feustel PJ; Cheema A; Postal ES; Cooper JA
Nucl Med Commun; 2003 May; 24(5):489-95. PubMed ID: 12717064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
